Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitochondrial Membranes01:45

Mitochondrial Membranes

16.6K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
16.6K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Metastasis02:30

Metastasis

6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia.

Science advances·2025
Same author

Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.

Nature reviews. Clinical oncology·2025
Same author

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

Cancer discovery·2023
Same author

Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.

Cancer discovery·2019
Same journal

Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals.

Current pharmacology reports·2025
Same journal

Feasibility and Safety of Targeting Mitochondria Function and Metabolism in Acute Myeloid Leukemia.

Current pharmacology reports·2025
Same journal

Exploring the Epigenetic and Metabolic Pathways for Antioxidant and Anti-Inflammatory Potentials of Tart Cherry Juice Concentrate.

Current pharmacology reports·2025
Same journal

Rapid diagnostics to enhance therapy selection for the treatment of bacterial infections.

Current pharmacology reports·2025
Same journal

Application of Metabolomics in Carcinogenesis and Cancer Prevention by Dietary Phytochemicals.

Current pharmacology reports·2025
Same journal

Pharmacodynamics (PD), Pharmacokinetics (PK) and PK-PD Modeling of NRF2 Activating Dietary Phytochemicals in Cancer Prevention and in Health.

Current pharmacology reports·2024
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.1K

Mitochondrial Dynamics in Blood Cancer Development and Progression.

Saurav Doshi1,2,3,4, Christina Glytsou1,2,3,4,5

  • 1Graduate Program in Pharmaceutical Sciences, School of Graduate Studies, Rutgers University, Piscataway, 08854 NJ USA.

Current Pharmacology Reports
|October 28, 2025
PubMed
Summary
This summary is machine-generated.

Blood cancer cells manipulate mitochondrial dynamics for growth and drug resistance. Targeting these processes offers new therapeutic strategies and predictive biomarkers for hematologic malignancies.

Keywords:
Blood cancerFissionFusionLeukemiaMitochondria

More Related Videos

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

7.4K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.1K
An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

7.4K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.9K

Area of Science:

  • Cell Biology
  • Cancer Biology
  • Mitochondrial Biology

Background:

  • Mitochondrial dynamics, involving fusion and fission, are crucial for cellular homeostasis.
  • Dysregulation of mitochondrial dynamics is linked to various chronic diseases.
  • Cancer cells, particularly blood cancers, exploit mitochondrial remodeling for survival and progression.

Purpose of the Study:

  • To review the role of mitochondrial dynamics in healthy cells.
  • To elaborate on how blood cancer cells hijack mitochondrial processes.
  • To explore therapeutic avenues targeting mitochondrial dynamics in hematologic malignancies.

Main Methods:

  • Review of recent research on mitochondrial dynamics in cancer.
  • Analysis of studies using cell lines, patient-derived samples, and xenograft models.
  • Investigation of regulatory mechanisms of mitochondrial dynamics proteins.

Main Results:

  • Blood cancer cells utilize mitochondrial plasticity for uncontrolled proliferation, stemness, and drug resistance.
  • Leukemia and lymphoma cells adapt to stress and evade therapy by manipulating mitochondria.
  • Mitochondrial dynamics proteins play specific roles in different hematologic malignancies and therapy resistance.

Conclusions:

  • Modulating mitochondrial dynamics presents a promising therapeutic strategy for hematologic malignancies.
  • Targeting mitochondrial dynamics regulators may serve as predictive biomarkers.
  • Further integrated studies are needed to fully exploit mitochondrial vulnerabilities in blood cancers.